Icosavax, Inc., a biopharmaceutical company, develops vaccines against infectious diseases. The company, with the help of its virus-like particle (VLP) platform technology, focuses primarily on life-threatening respiratory diseases. Its products in pipeline include IVX-121, a vaccine candidate with RSV target and is under Phase 1/1b clinical trial; IVX-A12, a respiratory syncytial virus (RSV) monovalent antigen candidate with RSV/human metapneumovirus (hMPV) bivalent target indication; IVX-241, a vaccine candidate with hMPV target; and IVX-411, an original receptor binding domain (RBD) sequence antigen with SARS-CoV-2 target indication and is under Phase 1/2 clinical trial. The company was incorporated in 2017 and is headquartered in Seattle, Washington.
Revenue of Icosavax, Inc. (ICVX)
Revenue in 2022 (TTM): $582 K
According to Icosavax, Inc.'s latest financial reports the company's current revenue (TTM) is $582 K. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Icosavax, Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2022 | $582 K | $-1,261,000 | $-95,058,000 | $-91,758,000 | $-88,458,000 |
| 2021 | $7.8 M | $7.72 M | $-64,902,000 | $-66,971,000 | $-67,999,000 |
| 2020 | $1.62 M | $-16,051,000 | $-18,709,000 | $-18,854,000 | $-19,185,000 |
| 2019 | $ | $-4,157,000 | $-5,398,000 | $-5,297,000 | $-5,196,000 |